Literature DB >> 29051990

Clinicopathologic implications of CD8+/Foxp3+ ratio and miR-574-3p/PD-L1 axis in spinal chordoma patients.

Ming-Xiang Zou1, Ke-Miao Guo1, Guo-Hua Lv1, Wei Huang2, Jing Li3, Xiao-Bin Wang4, Yi Jiang5, Xiao-Ling She5.   

Abstract

Currently, little is known about the interactions between microRNAs (miRNAs) and the PD-1/PD-L1 signaling pathway in chordoma, and data discussing the role of the immune milieu in chordoma prognosis are limited. We aimed to analyze the relationship between PD-L1, miR-574-3p, microenvironmental tumor-infiltrating lymphocytes (TILs) and clinicopathological features of spinal chordoma patients. PD-L1 expression and TILs (including Foxp3+, CD8+, PD-1+ and PD-L1+) were assessed by immunohistochemistry in tumor specimens of 54 spinal chordoma patients. MiRNAs microarray and bioinformatical analysis were used to identify miRNAs potentially regulating PD-L1 expression, which were further validated by quantitative RT-PCR. miR-574-3p was identified to potentially regulate PD-L1 expression in chordoma, which inversely correlated with PD-L1. Positive PD-L1 expression on tumor cells was associated with advanced stages (P = 0.041) and TILs infiltration (P = 0.005), whereas decreased miR-574-3p level correlated with higher muscle invasion (P = 0.012), more severe tumor necrosis (P = 0.022) and poor patient survival. Importantly, a patient subgroup with PD-L1+/miR-574-3plow chordoma phenotype was significantly associated with worse local recurrence-free survival (LRFS) (P = 0.026). PD-1+ TILs density was associated with surrounding muscle invasion (P = 0.014), and independently portended poor LRFS (P = 0.040), while PD-L1+ TILs showed tendencies of less aggressive clinical outcomes. Multivariate analysis of OS only found CD8+/Foxp3+ ratio to be independent prognostic factor (P = 0.022). These findings may be useful to stratify patients into prognostic groups and provide a rationale for the use of checkpoint blockade therapy, possibly by administering miR-574-3p mimics, in spinal chordoma.

Entities:  

Keywords:  CD8; Foxp3; PD-1; PD-L1; Spinal chordoma; miR-574-3p

Mesh:

Substances:

Year:  2017        PMID: 29051990     DOI: 10.1007/s00262-017-2080-1

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  16 in total

1.  Immune Checkpoint Inhibitors Have Clinical Activity in Patients With Recurrent Chordoma.

Authors:  Andrew J Bishop; Behrang Amini; Heather Lin; Shaan M Raza; Shreyaskumar Patel; David R Grosshans; Amol Ghia; Ahsan Farooqi; B Ashleigh Guadagnolo; Devarati Mitra; Kadir C Akdemir; Alexander J Lazar; Wei-Lien Wang; Christopher Alvarez-Breckenridge; Justin Bird; Laurence D Rhines; Neeta Somaiah; Anthony P Conley
Journal:  J Immunother       Date:  2022-08-04       Impact factor: 4.912

2.  Single-cell transcriptome profiling reveals intra-tumoral heterogeneity in human chordomas.

Authors:  Wanru Duan; Boyan Zhang; Xinqiang Li; Wei Chen; Shanhang Jia; Zong Xin; Qiang Jian; Fengzeng Jian; Dean Chou; Zan Chen
Journal:  Cancer Immunol Immunother       Date:  2022-01-27       Impact factor: 6.630

3.  Key questions about the checkpoint blockade-are microRNAs an answer?

Authors:  Mihnea Dragomir; Baoqing Chen; Xiao Fu; George A Calin
Journal:  Cancer Biol Med       Date:  2018-05       Impact factor: 4.248

4.  A four-factor immune risk score signature predicts the clinical outcome of patients with spinal chordoma.

Authors:  Ming-Xiang Zou; Yue Pan; Wei Huang; Tao-Lan Zhang; David Escobar; Xiao-Bin Wang; Yi Jiang; Xiao-Ling She; Guo-Hua Lv; Jing Li
Journal:  Clin Transl Med       Date:  2020-01

Review 5.  Recent Findings in the Regulation of Programmed Death Ligand 1 Expression.

Authors:  Xiangfeng Shen; Lihong Zhang; Jicheng Li; Yulin Li; Yishu Wang; Zhi-Xiang Xu
Journal:  Front Immunol       Date:  2019-06-14       Impact factor: 7.561

6.  MiRNA-574-3p inhibits cell progression by directly targeting CCND2 in colorectal cancer.

Authors:  Wen-Cui Li; Yan-Qiong Wu; Bo Gao; Chao-Yun Wang; Juan-Juan Zhang
Journal:  Biosci Rep       Date:  2019-12-20       Impact factor: 3.840

7.  Development and Validation of a 6-miRNA Prognostic Signature in Spinal Chordoma.

Authors:  Wei Huang; Yi-Guo Yan; Wen-Jun Wang; Zhi-Hua Ouyang; Xue-Lin Li; Tao-Lan Zhang; Xiao-Bin Wang; Bing Wang; Guo-Hua Lv; Jing Li; Ming-Xiang Zou
Journal:  Front Oncol       Date:  2020-10-27       Impact factor: 6.244

Review 8.  Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence.

Authors:  Jeffrey I Traylor; Mark N Pernik; Aaron R Plitt; Michael Lim; Tomas Garzon-Muvdi
Journal:  Cancers (Basel)       Date:  2021-05-17       Impact factor: 6.639

Review 9.  Translational Windows in Chordoma: A Target Appraisal.

Authors:  Samantha E Hoffman; Sally A Al Abdulmohsen; Saksham Gupta; Blake M Hauser; David M Meredith; Ian F Dunn; Wenya Linda Bi
Journal:  Front Neurol       Date:  2020-07-08       Impact factor: 4.003

Review 10.  miRNA-based biomarkers, therapies, and resistance in Cancer.

Authors:  Boxue He; Zhenyu Zhao; Qidong Cai; Yuqian Zhang; Pengfei Zhang; Shuai Shi; Hui Xie; Xiong Peng; Wei Yin; Yongguang Tao; Xiang Wang
Journal:  Int J Biol Sci       Date:  2020-07-19       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.